NEW YORK, Nov 21 – Structural Bioinformatics of San Diego said Tuesday it had licensed its SBdBase database of 3-dimensional protein structures to De Novo Pharmaceuticals.
Under the terms of the deal, De Novo will have access to multiple therapeutic target classes, Structural Bioinformatics said in a statement. Financial terms were not disclosed.
" The combination of SBI's proprietary protein structures with De Novo's powerful proprietary drug design algorithms extends our design platform from experimentally determined protein structures to the broader world of sequence-based information,” David Bailey, De Novo's CEO, said.
“The agreement with SBI will allow De Novo to expand its drug design partnerships with early-stage genomics targets," he said.
De Novo of Cambridge, UK, uses proprietary computational software for drug design to create lead molecules as candidates for drug development.
De Novo has collaborated with British Biotechnology and Aventis Pharma.